% | $
Quotes you view appear here for quick access.

Inovio Pharmaceuticals, Inc. Message Board

  • desperatca desperatca Jul 12, 2013 4:44 PM Flag


    The $2 price target set before the pump has now been lowered during the dump on wednesday to 70 cents by Zacks

    "Analysts at Zacks downgraded shares of Inovio Pharmaceuticals from an outperform rating to a neutral rating in a research note to investors on Wednesday, June 19th. They now have a $0.70 price target on the stock."

    Plus ALL the stocks technicals (4 or 5 major big ones) on the chart are showing a hard drop coming off of 1.50 with severe overbought signals. Classic severe "dump" technical signals after a huge pump.

    Journalist are murdering it too now. This is an article just put out at InsiderMonkey (Motley Fool) this morning.10:15 JULY 12th.

    Earlier this week, Inovio Pharmaceuticals released data from a study of its universal H7N9 vaccine that demonstrated 100% protection in vaccinated animals. Also, just yesterday, Inovio released the results of a study involving its Cellectra electroporation delivery technology, which improved response rates for its next-generation HIV vaccine to 52% from 7% in terms of CD8 T-cell response rates.

    I'm not planning to take a thing away from Inovio Pharmaceuticals here, as these are important and solid results. Shareholders, though, are doing themselves a disservice by ignoring other aspects that I feel make Inovio much more of a risk than these results might indicate.

    To begin with, having a vaccine that works in animals is no guarantee it'll be safe and effective in humans. To that end, even getting a vaccine approved for H7N9 doesn't mean it'll be profitable, as governments around the globe would need to buy a lot of the product to make it worthwhile. With a better understanding of how to quarantine infectious diseases nowadays, an H7N9 vaccine may not be a big moneymaker for INO. It's also not the only fish in the pond researching for a vaccine, either.

    The other aspect to consider here is INO's history. Despite being founded 30 years ago, there isn't a whole lot to show for it other than an accumulated deficit of $238.6 million as of its latest quarter. To add to that, it's funded its business with countless dilutive share offerings and warrants, which have increased the number of outstanding shares from approximately 13 million in 2003 to a whopping 156 million as of the first quarter of 2013. Inovio has had shareholders' hopes up before and it's crushed them every time. I'm not sure how this time will be any different, and I'd suggest keeping your distance.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
10.41-0.28(-2.62%)11:07 AMEDT